Patent ID: 9657089
Date: 2017-05-23
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of treatment, alleviating the effects, or delay of a neurodegenerative disease in a subject comprising: (A) administering of a pharmaceutically effective dose of an isolated monoclonal antibody to a subject in need thereof; or (B) administering of a pharmaceutically effective dose of a pharmaceutical composition comprising an isolated monoclonal antibody in combination with at least one pharmaceutically acceptable carrier or excipient to a subject in need thereof; wherein the neurodegenerative disease is selected from the group consisting of mild cognitive impairment, Alzheimer's disease, a Familial Alzheimer's dementia, and neurodegeneration in Down Syndrome; the monoclonal antibody binds to Aβ peptides between amino acid position 11 and an N-terminal pyroglutamate, AβpGlu(11), or variants thereof; the monoclonal antibody has a dissociation constant (K the variable part of the light chain of the antibody has the nucleotide sequence of SEQ ID NO: 51 or the amino acid sequence of SEQ ID NO: 52.